Non-Small Cell Lung Cancer

Access ESMO scientific and educational resources on this topic
Recent medwireNews and resources from conferences are for ESMO Members only.

Reporting from AACR 2018 in Chicago, Marina Garassino says that we now have multiple possibilities in first-line immunotherapy for metastatic non-small cells lung cancer (NSCLC). The results from two important phase III studies (KEYNOTE 189 and Check-Mate 227) were presented at the meeting and simultaneously published in the NEJM. Abstracts:

  • Keynote-189 phase III study
  • Results from the Check-Mate 227 phase III study